What do systematic reviews say?

Pregabalin vs placebo

It is very uncertain whether summary of findings ‐ Pharmacological intervention (pregabalin) changes treatment‐related adverse effects compared with placebo (very low certainty).

• Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
  RR 1.33
  1 study · 22 participants
  Very low

Summary of findings ‐ initiation of penicillin prophylaxis vs placebo

• Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 457 participants
  Low

Prophylaxis with standard therapeutic factor concentrate vs pegylated liposome FVIII formulation

• Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 143 participants
  Low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… showed no clear difference in side effects or other adverse events compared with placebo, no intervention or usual care (with or without placebo) (low certainty).

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes

  Up to 10 days postoperative
  RD 0.034 [-0.32, 0.38]
  2 studies · 59 participants
  Low

Cisapride vs placebo

• Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Very low

Summary of findings ‐ withdrawal of penicillin prophylaxis vs continuation

Summary of findings ‐ withdrawal of penicillin prophylaxis showed no clear difference in adverse effects: incidences of nausea and vomiting compared with continuation (low certainty).

• Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease 2021 · Cochrane Headline outcomes only
  OR 1.99 [0.18, 22.12]
  1 study · 400 participants
  Low

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo mouthwash

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in side effects or other adverse events requiring withdrawal compared with placebo (placebo solution/mouthwash) (moderate certainty).

• Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or… 2018 · Cochrane All outcomes

  7 days
  RD 0.00 [-0.04, 0.04]
  2 studies · 128 participants
  Moderate